D6M Stock Overview
Engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
genedrive plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.022 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.002 |
| Beta | -0.10 |
| 1 Month Change | 91.30% |
| 3 Month Change | 193.33% |
| 1 Year Change | -80.00% |
| 3 Year Change | -95.11% |
| 5 Year Change | n/a |
| Change since IPO | -98.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| D6M | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 12.8% | 1.4% | 0.5% |
| 1Y | -80.0% | -4.5% | 7.2% |
Return vs Industry: D6M underperformed the German Life Sciences industry which returned -4.5% over the past year.
Return vs Market: D6M underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| D6M volatility | |
|---|---|
| D6M Average Weekly Movement | 155.2% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D6M's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: D6M's weekly volatility has increased from 93% to 155% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 43 | Gino Miele | www.genedriveplc.com |
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides c system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.
genedrive plc Fundamentals Summary
| D6M fundamental statistics | |
|---|---|
| Market cap | €15.89m |
| Earnings (TTM) | -€8.54m |
| Revenue (TTM) | €604.50k |
26.3x
P/S Ratio-1.9x
P/E RatioIs D6M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D6M income statement (TTM) | |
|---|---|
| Revenue | UK£501.00k |
| Cost of Revenue | UK£4.18m |
| Gross Profit | -UK£3.67m |
| Other Expenses | UK£3.40m |
| Earnings | -UK£7.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | -733.33% |
| Net Profit Margin | -1,412.18% |
| Debt/Equity Ratio | 0% |
How did D6M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 17:27 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
genedrive plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Brewer | Cavendish |
| Vadim Alexandre Khalil | Daniel Stewart & Company |
| John Savin | Edison Investment Research |